Robert A. Chase

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

Bruce A. Malcolm, R. Liu, Frederick Lahser et al. · Antimicrobial Agents and Chemotherapy · 2006 · 316 citations · Full text

Viral Replication, Hepatitis C Virus, Immunology +17

Discovery of (1 <i>R</i> ,5 <i>S</i> )- <i>N</i> -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( <i>S</i> )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( <i>S</i> )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Srikanth Venkatraman, Stéphane Bogen, Ashok Arasappan et al. · Journal of Medicinal Chemistry · 2006 · 278 citations · Full text

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

Xinchun Tong, Robert A. Chase, Angela Skelton et al. · Antiviral Research · 2006 · 233 citations

Drug Resistance Analysis, Molecular Virology, Genetics +8

Lassa Fever in the United States

Gary P. Holmes, Joseph B. McCormick, Susan C. Trock et al. · New England Journal of Medicine · 1990 · 155 citations · Full text

Malaria, Disease Outbreak, Western Africa +16

Characterization of resistance mutations against HCV ketoamide protease inhibitors

Xinchun Tong, Stéphane Bogen, Robert A. Chase et al. · Antiviral Research · 2008 · 127 citations

Drug Discovery, Resistance Mutation (Virology), Resistance Mutations +2